Review



prs shepha2 vector  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    OriGene prs shepha2 vector
    (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. <t>shEphA2</t> represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.
    Prs Shepha2 Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prs+shepha2+vector/pmc06103826-61-7-9?v=OriGene
    Average 90 stars, based on 3 article reviews
    prs shepha2 vector - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma"

    Article Title: EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

    Journal: International journal of cancer

    doi: 10.1002/ijc.31405

    (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. shEphA2 represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.
    Figure Legend Snippet: (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. shEphA2 represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.

    Techniques Used: Quantitative RT-PCR, Plasmid Preparation, Transfection, Clone Assay, Migration, Western Blot, Expressing



    Similar Products

    prs shepha2 vector  (OriGene)
    90
    OriGene prs shepha2 vector
    (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. <t>shEphA2</t> represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.
    Prs Shepha2 Vector, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prs+shepha2+vector/pmc06103826-61-7-9?v=OriGene
    Average 90 stars, based on 1 article reviews
    prs shepha2 vector - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. shEphA2 represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.

    Journal: International journal of cancer

    Article Title: EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

    doi: 10.1002/ijc.31405

    Figure Lengend Snippet: (A–B) Validation of up- (A) and down- (B) regulated targets after EphA2 silencing by RT-qPCR in A673 and TC252 models. CTRL represents the mean from both the parental and the control vector transfected pool. shEphA2 represents the mean from the two representative clones employed through the previous experiments. (C) Migration assay in Boyden chambers after ADAM19 silencing in A673 cell line. siCTRL (= non-targeting siRNA) was set as reference. (D) Representative western blot showing ADAM19 expression and phosphorylation of EphA2 and ERK after siRNA silencing in A673 cell line. siCTRL = non-targeting siRNA. (E) Representative western blot showing ADAM19 expression and EphA2 phosphorylation after treatment with 50 nM Trametinib in the A673 cell line. ERK and p-ERK are shown as treatment efficiency controls. (F) Migration assay in Boyden chambers after ADAM19 silencing in RH1 EphA2 reintroduction model. REphWT plus siCTRL (= non-targeting siRNA) was set as reference. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at least three different experiments: *p ≤ 0.05 **p ≤ 0.01.

    Article Snippet: A673 and TC252 cells stably transfected with pRS-shEphA2 vector (Origene #TR320327) were selected with 0.5 μg/mL and 0.2 μg/mL of puromycin (Sigma-Aldrich), respectively, for 14 days.

    Techniques: Quantitative RT-PCR, Plasmid Preparation, Transfection, Clone Assay, Migration, Western Blot, Expressing